348 related articles for article (PubMed ID: 12657846)
1. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
Ibrahim AE; Feldman J; Karim A; Kharasch ED
Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
[TBL] [Abstract][Full Text] [Related]
2. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam.
Ibrahim A; Karim A; Feldman J; Kharasch E
Anesth Analg; 2002 Sep; 95(3):667-73, table of contents. PubMed ID: 12198057
[TBL] [Abstract][Full Text] [Related]
3. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate.
Kharasch ED; Whittington D; Hoffer C
Anesthesiology; 2004 Sep; 101(3):729-37. PubMed ID: 15329598
[TBL] [Abstract][Full Text] [Related]
4. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: noninvasive assessment by use of pupillary miosis.
Kharasch ED; Walker A; Hoffer C; Sheffels P
Clin Pharmacol Ther; 2004 Nov; 76(5):452-66. PubMed ID: 15536460
[TBL] [Abstract][Full Text] [Related]
5. Effects of parecoxib, a parenteral COX-2-specific inhibitor, on the pharmacokinetics and pharmacodynamics of propofol.
Ibrahim A; Park S; Feldman J; Karim A; Kharasch ED
Anesthesiology; 2002 Jan; 96(1):88-95. PubMed ID: 11753007
[TBL] [Abstract][Full Text] [Related]
6. The role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactions.
Kharasch ED; Russell M; Mautz D; Thummel KE; Kunze KL; Bowdle A; Cox K
Anesthesiology; 1997 Jul; 87(1):36-50. PubMed ID: 9232132
[TBL] [Abstract][Full Text] [Related]
7. Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.
Kharasch ED; Hoffer C; Walker A; Sheffels P
Clin Pharmacol Ther; 2003 Mar; 73(3):199-208. PubMed ID: 12621385
[TBL] [Abstract][Full Text] [Related]
8. A pilot evaluation of alfentanil-induced miosis as a noninvasive probe for hepatic cytochrome P450 3A4 (CYP3A4) activity in humans.
Phimmasone S; Kharasch ED
Clin Pharmacol Ther; 2001 Dec; 70(6):505-17. PubMed ID: 11753266
[TBL] [Abstract][Full Text] [Related]
9. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
Kharasch ED; Hoffer C; Whittington D; Sheffels P
Clin Pharmacol Ther; 2004 Sep; 76(3):250-69. PubMed ID: 15371986
[TBL] [Abstract][Full Text] [Related]
10. Metabolism of alfentanil by cytochrome p4503a (cyp3a) enzymes.
Klees TM; Sheffels P; Dale O; Kharasch ED
Drug Metab Dispos; 2005 Mar; 33(3):303-11. PubMed ID: 15557344
[TBL] [Abstract][Full Text] [Related]
11. Single-point sampling for assessment of constitutive, induced, and inhibited cytochrome P450 3A activity with alfentanil or midazolam.
Chaobal HN; Kharasch ED
Clin Pharmacol Ther; 2005 Nov; 78(5):529-39. PubMed ID: 16321619
[TBL] [Abstract][Full Text] [Related]
12. Paradoxical role of cytochrome P450 3A in the bioactivation and clinical effects of levo-alpha-acetylmethadol: importance of clinical investigations to validate in vitro drug metabolism studies.
Kharasch ED; Whittington D; Hoffer C; Krudys K; Craig K; Vicini P; Sheffels P; Lalovic B
Clin Pharmacokinet; 2005; 44(7):731-51. PubMed ID: 15966756
[TBL] [Abstract][Full Text] [Related]
13. Voriconazole, but not terbinafine, markedly reduces alfentanil clearance and prolongs its half-life.
Saari TI; Laine K; Leino K; Valtonen M; Neuvonen PJ; Olkkola KT
Clin Pharmacol Ther; 2006 Nov; 80(5):502-8. PubMed ID: 17112806
[TBL] [Abstract][Full Text] [Related]
14. Assessment of cytochrome P450 3A4 activity during the menstrual cycle using alfentanil as a noninvasive probe.
Kharasch ED; Russell M; Garton K; Lentz G; Bowdle TA; Cox K
Anesthesiology; 1997 Jul; 87(1):26-35. PubMed ID: 9232131
[TBL] [Abstract][Full Text] [Related]
15. Ritonavir's role in reducing fentanyl clearance and prolonging its half-life.
Olkkola KT; Palkama VJ; Neuvonen PJ
Anesthesiology; 1999 Sep; 91(3):681-5. PubMed ID: 10485779
[TBL] [Abstract][Full Text] [Related]
16. Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).
Kharasch ED; Bedynek PS; Hoffer C; Walker A; Whittington D
Anesthesiology; 2012 Feb; 116(2):432-47. PubMed ID: 22273859
[TBL] [Abstract][Full Text] [Related]
17. Pharmacology of epidural fentanyl, alfentanil, and sufentanil in volunteers.
Coda BA; Brown MC; Schaffer R; Donaldson G; Jacobson R; Hautman B; Shen DD
Anesthesiology; 1994 Nov; 81(5):1149-61. PubMed ID: 7978473
[TBL] [Abstract][Full Text] [Related]
18. Influence of age on the pharmacokinetics and pharmacodynamics of oral transmucosal fentanyl citrate.
Kharasch ED; Hoffer C; Whittington D
Anesthesiology; 2004 Sep; 101(3):738-43. PubMed ID: 15329599
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity of intravenous and oral alfentanil and pupillary miosis as minimally invasive and noninvasive probes for hepatic and first-pass CYP3A activity.
Kharasch ED; Walker A; Hoffer C; Sheffels P
J Clin Pharmacol; 2005 Oct; 45(10):1187-97. PubMed ID: 16172184
[TBL] [Abstract][Full Text] [Related]
20. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
